Wholesale · Research use only
Wholesale Orforglipron (LY3502970)
A first-in-class non-peptide, orally active GLP-1 receptor agonist in late-stage clinical development by Eli Lilly. Unlike injectable peptide agonists, Orforglipron is a small molecule designed for once-daily oral administration — removing cold-chain constraints and simplifying research logistics. Supplied research-grade to CROs, R&D groups and qualified B2B distributors.
No cold chain required≥98% HPLC & LC-MSBatch COAs
GMP · ISO · HACCPUK & Berlin manufacturingThird-party testedManufacturer direct since 2018
Overview
An oral GLP-1 agonist, not a peptide
No cold chain
Stable at ambient temperature, cutting storage and shipping overhead for multi-site programmes.
Small molecule
Bypasses the structural limits that confine peptide GLP-1 agonists to injectable formats.
Phase III
In late-stage development for obesity and type 2 diabetes.
Orforglipron (LY3502970) is a first-in-class non-peptide, orally active GLP-1 receptor agonist currently in late-stage clinical development by Eli Lilly. Unlike peptide-based GLP-1 agonists such as semaglutide and tirzepatide, which require weekly subcutaneous injection and cold-chain storage, Orforglipron is a small molecule designed for once-daily oral administration — removing cold-chain constraints and simplifying research logistics significantly.SARMs Direct supplies wholesale Orforglipron in research-grade bulk quantities to CROs, pharmaceutical R&D groups, universities and qualified B2B distributors. All supply is strictly for research use only and is not available for human consumption or clinical use.
Compound specifications
Orforglipron at a glance
| Compound name | Orforglipron |
| Development code | LY3502970 |
| Compound class | Non-peptide GLP-1 receptor agonist (small molecule) |
| CAS number | 2381246-44-0 |
| Developer | Eli Lilly and Company |
| Administration | Oral, once daily |
| Development status | Phase III (obesity & type 2 diabetes) |
| Purity | ≥98% (HPLC & LC-MS verified) |
| Supply form | Raw powder; encapsulated on request |
| Storage | Cool, dry place. No cold chain required. Protect from light and moisture. |
Available formats & MOQs
Supply options
FORMAT 01
Raw powder
Pilot and scale quantities available. Supplied in research-grade bulk packaging with tamper-evident seals, COA included. Contact us for MOQ and pricing based on your research volume.FORMAT 02
Encapsulated
Available on request for eligible B2B partners. Contact us to discuss dose and quantity requirements for your programme.FORMAT 03
White label & formulation support
Available for qualified B2B partners in R&D contexts. See white label →Research context
Mechanism & clinical background
All data cited refers to publicly available clinical trial readouts. All products are supplied for research purposes only and are not intended for human or veterinary use. No claims of safety or efficacy are made.
Orforglipron acts as a selective agonist at the glucagon-like peptide-1 (GLP-1) receptor — the same receptor targeted by the approved injectable agents semaglutide and tirzepatide. As a small molecule rather than a peptide, it bypasses the structural limitations that have historically confined GLP-1 agonists to injectable formats, making it the subject of significant pharmaceutical and academic interest.Phase III clinical programmes have been investigating Orforglipron for weight management in adults with obesity and for glycaemic control in type 2 diabetes. Publicly reported data from earlier trials indicates double-digit mean weight reduction at higher doses in non-diabetic cohorts, alongside meaningful HbA1c reductions in diabetic populations. Tolerability profiles are consistent with the GLP-1 class — predominantly gastrointestinal adverse events including nausea, diarrhoea and constipation.Its oral format removes cold-chain requirements, simplifying logistics for multi-site research programmes and reducing operational overhead compared with injectable alternatives.
Research comparison
GLP-1 pathway agents
| Orforglipron | Oral (daily) |
| Retatrutide | Injectable (weekly) |
| Semaglutide | Injectable (weekly) |
| Tirzepatide | Injectable (weekly) |
ⓘ For research reference only. Efficacy data is not directly comparable across studies or compounds.
Quality & documentation
Every batch documented
- GMP-certified manufacturing
- ISO quality management system
- HACCP-compliant production controls
- Independent third-party testing — HPLC, LC-MS, ICP-MS
- Certificate of Analysis (COA) issued per batch
- MSDS available on request
- Batch and lot traceability records
- Research Use Only labelling and export documentation included
Who orders wholesale Orforglipron
B2B buyers we supply
Contract Research Organisations
Metabolic disease and obesity research programmes.
University research groups
GLP-1 receptor pharmacology studies.
Pharmaceutical R&D teams
Comparator compound supply for GLP-1 class research.
Qualified B2B distributors
Specialist research compound distribution.
Legal & safety notice
Orforglipron is an investigational research compound. It is not approved by any regulatory authority for human consumption, medical treatment or clinical application. All purchases are restricted to qualified institutional or professional B2B buyers. Buyers are responsible for ensuring compliance with applicable regulations in their jurisdiction.Related compounds
Buyers sourcing Orforglipron also enquire about
For peptide-based weight management compounds including semaglutide analogues and related GLP-1 pathway peptides, visit our sister site Peptide-Direct →
Request a wholesale Orforglipron quote
Provide your organisation details, required quantity and shipping destination for a tailored quotation. COAs, pricing and batch documentation available on request — qualified B2B buyers only.
Frequently asked questions
What is Orforglipron (LY3502970)?
Orforglipron is a non-peptide, orally active GLP-1 receptor agonist developed by Eli Lilly. It is a small molecule designed for once-daily oral administration, currently in Phase III development for obesity and type 2 diabetes. Available for research use only.
What is the CAS number for Orforglipron?
The CAS number for Orforglipron is 2381246-44-0.
Is Orforglipron available for consumer use?
No. It is an investigational compound for research use only. It is not approved for human consumption, medical treatment or clinical use. Supply is restricted to qualified institutional and professional B2B buyers.
How does Orforglipron differ from semaglutide or tirzepatide?
Orforglipron is a small-molecule oral GLP-1 agonist. Semaglutide and tirzepatide are injectable peptides requiring weekly administration and cold-chain storage. Orforglipron's oral format removes cold-chain requirements and simplifies logistics for research operations.
Do you provide COAs for wholesale Orforglipron?
Yes. Batch COAs and full QC documentation are available on request for all qualified buyers. See how testing works.
Can you supply Orforglipron for white label or formulation work?
Yes, for eligible B2B partners in R&D contexts. Contact us to discuss your specific requirements.
All products are sold strictly for laboratory research purposes and are not for human consumption.